Get the Stockscreener App
2.41
4.78%
0.11
After Hours:
2.41
Century Therapeutics Inc stock is traded at $2.41, with a volume of 1.26M.
It is up +4.78% in the last 24 hours and up +6.64% over the past month.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
See More
Previous Close:
$2.30
Open:
$2.24
24h Volume:
1.26M
Relative Volume:
1.14
Market Cap:
$434.66M
Revenue:
$109.16M
Net Income/Loss:
$-107.78M
P/E Ratio:
-2.1784
EPS:
-1.1063
Net Cash Flow:
$-95.45M
1W Performance:
+10.55%
1M Performance:
+6.64%
6M Performance:
+146.07%
1Y Performance:
+319.13%
1-Day Range:
$2.22
$2.41
1-Week Range:
$2.21
$2.41
52-Week Range:
$0.435
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.41 | 413.01M | 109.16M | -107.78M | -95.45M | -1.1063 |
VRTX
Vertex Pharmaceuticals Inc
|
468.42 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
618.03 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.40 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.18 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
169.51 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | TD Cowen | Buy |
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight - GlobeNewswire Inc.
Century Therapeutics Inc (IPSC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Century Therapeutics Inc (IPSC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Century Therapeutics Inc (IPSC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Century Therapeutics Inc (IPSC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Century Therapeutics Inc (IPSC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Century Therapeutics Inc (IPSC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Century Therapeutics Inc (IPSC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Century Therapeutics Inc (IPSC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Century Therapeutics Inc (IPSC) Institutional Confidence - TradingKey
Century Therapeutics amends chief scientific officer contract to part-time role - Investing.com
Century Therapeutics (IPSC) shifts Chief Scientific Officer to part-time role with new pay terms - Stock Titan
Century Therapeutics SVP Carr sells $3,691 in company stock By Investing.com - Investing.com India
Century Therapeutics SVP Carr sells $3,691 in company stock - Investing.com
Century Therapeutics executive Gregory Russotti sells $5,767 in stock By Investing.com - Investing.com Nigeria
Century Therapeutics executive Gregory Russotti sells $5,767 in stock - Investing.com
Century Therapeutics (IPSC) executive sells shares to cover RSU tax withholding - Stock Titan
Tax-related share sale by Century Therapeutics (IPSC) SVP Carr - Stock Titan
Century Therapeutics (IPSC) CEO reports 13,849-share tax withholding on RSU vesting - Stock Titan
Century Therapeutics (IPSC) CSO reports tax withholding of shares and restated holdings - Stock Titan
Century Therapeutics Shareholders Approve Directors and Share Increase - The Globe and Mail
Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation - Yahoo Finance
Century Therapeutics (IPSC) director Alessandro Riva granted 74,000 stock options - Stock Titan
Director Daphne Quimi receives 74,000 stock options at Century Therapeutics (NASDAQ: IPSC) - Stock Titan
Century Therapeutics (IPSC) director receives grant of 74,000 stock options - Stock Titan
Century Therapeutics (IPSC) director granted 74,000 stock options at $2.24 - Stock Titan
Century Therapeutics (IPSC) awards 74,000 stock options to director Kimberly Blackwell - Stock Titan
Century Therapeutics (IPSC) shareholders back higher authorized shares and board slate - Stock Titan
Insider sale notice for IPSC (NASDAQ: IPSC) — 2,584 shares planned; prior disposals listed - Stock Titan
Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813 - Insider Monkey
10 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Mizuho Securities Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Century Therapeutics (IPSC) executive logs small automatic share sale for taxes - Stock Titan
Century Therapeutics (IPSC) SVP’s automatic 249-share sale covers RSU tax withholding - Stock Titan
Century Therapeutics (NASDAQ: IPSC) CEO has 463 shares withheld for RSU taxes - Stock Titan
Century Therapeutics, Inc. (IPSC) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow (NASDAQ:IPSC) 2026-06-09 - Seeking Alpha
Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Century Therapeutics, Inc. (IPSC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Century Therapeutics Advances CNTY-813 Diabetes Cell Therapy - TipRanks
Century Therapeutics presents preclinical data on diabetes therapy By Investing.com - Investing.com South Africa
Century Therapeutics presents preclinical data on diabetes therapy - Investing.com
Century Therapeutics (NASDAQ: IPSC) details CNTY-813 diabetes cell therapy data - Stock Titan
Experimental islet therapy targets Type 1 diabetes without immunosuppression - Stock Titan
IPSC (NASDAQ: IPSC) Form 144: proposed sale of vested common shares - Stock Titan
Number of shareholders of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
Century Therapeutics (IPSC) Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Advances - newsline.com
Century Therapeutics Price Target Announced at $8.00/Share by Mizuho - Moomoo
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Mizuho Initiates Century Therapeutics at Outperform - Moomoo
Century Therapeutics (IPSC) Inches Higher, Approaches Key Resistance LevelVWAP Deviation - newsline.com
This GE Aerospace analyst begins coverage on a bullish note; here are top 5 initiations for Wednesday - MSN
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):